Literature DB >> 9806189

No difference in survival between sporadic, familial and hereditary prostate cancer.

H Grönberg1, L Damber, B Tavelin, J E Damber.   

Abstract

OBJECTIVE: To estimate the survival of men with familial prostate cancer and compare them with prostate cancer cases unselected for family history. PATIENTS AND METHODS: The overall and prostate cancer-specific survival was calculated in two large (249 and 304 men, respectively) population-based cohorts of men with familial prostate cancer. The tumour grade at diagnosis was also obtained in one of the cohorts.
RESULTS: There were no significant differences in either overall or prostate cancer-specific survival between familial and sporadic cases. The spectrum of tumour grades at diagnosis in familial cases did not differ from that in a population with prostate cancer unselected for family history.
CONCLUSION: No differences in treatment between men with or without a positive family history of prostate cancer are justified, based on the result from this study.

Entities:  

Mesh:

Year:  1998        PMID: 9806189     DOI: 10.1046/j.1464-410x.1998.00801.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  9 in total

1.  Hereditary and familial prostate cancer: biologic aggressiveness and recurrence.

Authors:  S R Potter; A W Partin
Journal:  Rev Urol       Date:  2000

2.  Information recovery in cancer families: value for risk estimations.

Authors:  Hassan Roudgari; Lindsey F Masson; Neva E Haites
Journal:  Fam Cancer       Date:  2007-05-23       Impact factor: 2.375

Review 3.  Genetic susceptibility to prostate cancer: a review.

Authors:  Bas A J Verhage; Lambertus A L M Kiemeney
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

Review 4.  Inherited predisposition to prostate cancer.

Authors:  Bas A J Verhage; Lambertus A L M Kiemeney
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

Review 5.  New insights and candidate genes and their implications for care of patients with hereditary prostate cancer.

Authors:  H L Kim; G D Steinberg
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

6.  Urologists' and GPs' knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands.

Authors:  Ruben Cremers; Christi van Asperen; Paul Kil; Hans Vasen; Tjerk Wiersma; Inge van Oort; Lambertus Kiemeney
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

7.  The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.

Authors:  Ruben G Cremers; Katja K Aben; Inge M van Oort; J P Michiel Sedelaar; Hans F Vasen; Sita H Vermeulen; Lambertus A Kiemeney
Journal:  Prostate       Date:  2016-03-14       Impact factor: 4.104

8.  Survival outcomes in men with a positive family history of prostate cancer: a registry based study.

Authors:  Mann Ang; Martin Borg; Michael E O'Callaghan
Journal:  BMC Cancer       Date:  2020-09-18       Impact factor: 4.430

9.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Authors:  Elena Castro; Chee Goh; David Olmos; Ed Saunders; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Nadiya Mahmud; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Emma Sawyer; Rosemary Wilkinson; Audrey Ardern-Jones; Steve Ellis; Debra Frost; Susan Peock; D Gareth Evans; Marc Tischkowitz; Trevor Cole; Rosemarie Davidson; Diana Eccles; Carole Brewer; Fiona Douglas; Mary E Porteous; Alan Donaldson; Huw Dorkins; Louise Izatt; Jackie Cook; Shirley Hodgson; M John Kennedy; Lucy E Side; Jacqueline Eason; Alex Murray; Antonis C Antoniou; Douglas F Easton; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.